Chul Kim, MD, on NSCLC With EGFR Exon 20 Insertions: First-Line Amivantamab/Chemotherapy vs Chemotherapy

September 16, 2026

Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (Abstract PL03.03). 

Related Content